Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 126

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 126
---
 on demand and payment for our tests; •exposure to foreign currency exchange rate fluctuations, conversions of currencies, and the risk of repatriation of certain foreign currencies; •natural disasters, political and economic instability, including wars (e.g., the war in Ukraine), terrorism and political unrest, outbreak of disease, boycotts, and other business restrictions; and •regulatory and compliance risks related to applicable anti -briberylaws, including requirements to maintain accurate information and control over activities that may fall within the purview of these laws. Any of these factors could significantly harm our existing relationships with international customers or derail our international expansion plans, which would cause our revenue and results of operations to suffer. In addition, we are exposed to a number of additional risks and challenges related to our current operations in Argentina and our potential future operations in Mexico. These risks include, among others, difficulties predicting the market for genetic testing for a specific market; competitive factors in this market, including challenges securing market share; local differences in customer demands and preferences and regulatory requirements; and many of the other risks of doing business internationally that are discussed above. Although we believe our regional operations could result in expanded long -termopportunities to address the genetic testing market in Latin America, and eventually, the U.S., this belief could turn out to be wrong, and we may never realize these or any other benefits we anticipate from our international expansion. Moreover, any future market expansion we may seek to establish may never produce sufficient revenue for us to recover our capital and other investments, and we could become subject to liabilities based on our involvement in any future operations. The materialization of any of these risks could materially harm our performance and prospects. We may be subject to legal proceedings and litigation, including product or service liability claims, which are costly to defend and could materially affect our business and results of operations. We may be party to lawsuits and legal proceedings in the normal course of business. These matters are often expensive and disruptive to normal business operations. We may face allegations, lawsuits, and regulatory inquiries, audits, and investigations regarding data privacy, security, labor and employment, consumer protection, practice of medicine, and intellectual property infringement, including claims related to privacy, patents, publicity, trademarks, copyrights, open -sourcesoftware, and other rights. A portion of the technologies we use incorporates open -sourcesoftware, and we may face claims claiming ownership of open source software or patents related to that software, rights to our intellectual property or breach of open source license terms, including a